全文获取类型
收费全文 | 467835篇 |
免费 | 30725篇 |
国内免费 | 3510篇 |
专业分类
耳鼻咽喉 | 6227篇 |
儿科学 | 10950篇 |
妇产科学 | 12373篇 |
基础医学 | 65219篇 |
口腔科学 | 13838篇 |
临床医学 | 37277篇 |
内科学 | 97661篇 |
皮肤病学 | 10425篇 |
神经病学 | 35626篇 |
特种医学 | 17459篇 |
外国民族医学 | 105篇 |
外科学 | 73277篇 |
综合类 | 11563篇 |
现状与发展 | 1篇 |
一般理论 | 109篇 |
预防医学 | 22504篇 |
眼科学 | 10830篇 |
药学 | 38418篇 |
4篇 | |
中国医学 | 2689篇 |
肿瘤学 | 35515篇 |
出版年
2021年 | 4233篇 |
2020年 | 2714篇 |
2019年 | 4235篇 |
2018年 | 6411篇 |
2017年 | 4888篇 |
2016年 | 5038篇 |
2015年 | 5791篇 |
2014年 | 8031篇 |
2013年 | 10820篇 |
2012年 | 14570篇 |
2011年 | 14950篇 |
2010年 | 9297篇 |
2009年 | 8578篇 |
2008年 | 13677篇 |
2007年 | 14685篇 |
2006年 | 14396篇 |
2005年 | 13295篇 |
2004年 | 13140篇 |
2003年 | 12763篇 |
2002年 | 12468篇 |
2001年 | 31848篇 |
2000年 | 32296篇 |
1999年 | 26511篇 |
1998年 | 6250篇 |
1997年 | 5098篇 |
1996年 | 4608篇 |
1995年 | 4240篇 |
1994年 | 3767篇 |
1993年 | 3480篇 |
1992年 | 17776篇 |
1991年 | 16518篇 |
1990年 | 15616篇 |
1989年 | 15370篇 |
1988年 | 13864篇 |
1987年 | 13215篇 |
1986年 | 12235篇 |
1985年 | 11327篇 |
1984年 | 7662篇 |
1983年 | 6279篇 |
1982年 | 3151篇 |
1979年 | 6028篇 |
1978年 | 3750篇 |
1977年 | 3324篇 |
1975年 | 3055篇 |
1974年 | 3537篇 |
1973年 | 3311篇 |
1972年 | 3245篇 |
1971年 | 3163篇 |
1970年 | 2862篇 |
1969年 | 2898篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
51.
52.
Y. Ermias I.A. Morgan K.M. Curtis M.K. Whiteman L.G. Horton L.B. Zapata 《Contraception》2019,99(5):300-305
ObjectiveIdentify factors associated with healthcare providers' frequency of depot medroxyprogesterone acetate (DMPA) provision to adolescents.Study designWe analyzed data from surveys mailed to a nationally representative sample of public-sector providers and office-based physicians (n=1984). We estimated adjusted odds ratios (aORs) and 95% confidence intervals (CIs) of factors associated with frequent DMPA provision to adolescents in the past year.ResultsAlthough most providers (>95%) considered DMPA safe for adolescents, fewer reported frequent provision (89% of public-sector providers; 64% of office-based physicians). Among public-sector providers, factors associated with lower odds of frequent provision included working in settings without Title X funding (aOR 0.44, 95% CI 0.30–0.64), reporting primary care as their primary clinical focus versus reproductive or adolescent health (aOR 0.42, 95% CI 0.28–0.61), and providing fewer patients with family planning services. Among office-based physicians, factors associated with lower odds of frequent provision included specializing in obstetrics/gynecology (aOR 0.50, 95% CI 0.27–0.91) and family medicine (aOR 0.21, 95% CI 0.09–0.47) versus adolescent medicine, completing training ≥15 versus <5 years ago (aOR 0.27, 95% CI 0.09–0.83), and reporting that 0–24% of patients pay with Medicaid or other government healthcare assistance versus ≥50% (aOR 0.23, 95% CI 0.09–0.61). The reason most commonly reported by providers for infrequent DMPA provision was patient preference for another method.ConclusionsWhile most providers reported frequently providing DMPA to adolescents, training on evidence-based recommendations for contraception, focused on subgroups of providers with lower odds of frequent DMPA provision, may increase adolescents' access to contraception.ImplicationsAlthough >95% of providers considered depot medroxyprogesterone (DMPA) a safe contraceptive for adolescents, only 89% of public-sector providers and 64% of office-based physicians reported frequently providing DMPA to adolescents. Provider training on evidence-based recommendations for contraception counseling and provision may increase adolescents' access to DMPA and all methods of contraception. 相似文献
53.
Prevention Science - This study aimed to evaluate the effectiveness of the drug and violence resistance educational program (PROERD) on short-term secondary outcomes, such as intentions to use... 相似文献
54.
55.
56.
57.
58.
59.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献60.
Tianjiao Lyu Yahui Jiang Nan Jia Xiaoxia Che Qin Li Yinhua Yu Keqin Hua Robert C. Bast Jr Weiwei Feng 《International journal of cancer. Journal international du cancer》2020,146(6):1553-1567
Detachment of cancer cells from the primary tumor and formation of spheroids in ascites is required for implantation metastasis in epithelial ovarian cancer (EOC), but the underlying mechanism of this process has not been thoroughly elucidated. To mimic this process, ovarian cancer cells were grown in 3D and 2D culture. Hey and OVCA433 spheroids exhibited decreased cell proliferation and enhanced adhesion and invasion. SMYD3 expression was elevated in ovarian carcinoma spheroids in association with increased H3K4 methylation. Depletion of SMYD3 by transient siRNA, stable shRNA knockdown and the SMYD3 inhibitor BCI-121 all decreased spheroid invasion and adhesion. Gene expression arrays revealed downregulation of integrin family members. Inhibition assays confirmed that invasion and adhesion of spheroids are mediated by ITGB6 and ITGAM. SMYD3-deficient cells regained the ability to invade and adhere after forced overexpression of SMYD3, ITGB6 and ITGAM. However, this biological ability was not restored by forced overexpression of SMYD3 in ITGB6- and/or ITGAM-deficient cancer cells. SMYD3 and H3K4me3 binding at the ITGB6 and ITGAM promoters was increased in spheroids compared to that in monolayer cells, and the binding was decreased when SMYD3 expression was inhibited, consistent with the expression changes in integrins. SMYD3 expression and integrin-mediated adhesion were also activated in an intraperitoneal xenograft model and in EOC patient spheroids. In vivo, SMYD3 knockdown inhibited tumor metastasis and reduced ascites volume in both the intraperitoneal xenograft model and a PDX model. Overall, our results suggest that the SMYD3-H3K4me3-integrin pathway plays a crucial role in ovarian cancer metastasis to the peritoneal surface. 相似文献